Back to all announcements

DJ Ananda Developments Plc hapac® Update

15 April 2019 
                            ANANDA DEVELOPMENTS PLC 
                          ("Ananda" or the "Company") 
The directors of Ananda Developments Plc (NEX:ANA) are pleased to provide 
shareholders with the following update. 
Ananda owns 15% of LHT, the 100% owner of hapac®, a technology for inhaling 
medicinal cannabis. 
As previously announced, the hapac® product was launched in Milan, Italy over 
the Christmas and New Year period 2018/2019.    Since the last update in March: 
  * hapac® continues to be sold in 6 stores in Italy 
  * rates of sale are positive and customer feedback sessions are ongoing to 
    ensure the product experience and mix is optimised 
  * hapac® will be released in a wider range of CBD content and two new 
    flavours in the coming weeks 
Further information on the hapac® product can be found at 
The Board has been reviewing several investment opportunities which have the 
potential to significantly increase in value for the benefit of Shareholders. 
The Company looks forward to providing an update in due course. 
The directors of the Company accept responsibility for the contents of this 
Ananda Developments plc                +44 (0)739 269 6517 
Executive Director 
Melissa Sturgess 
Investor Relations 
Jeremy Sturgess-Smith 
Peterhouse Capital Limited             +44 (0)20 7469 0930 
Corporate Finance 
Fungai Ndoro 
Mark Anwyl 
Corporate Broker Lucy Williams 
Duncan Vasey 
Notes to editors 
About Ananda Developments PLC 
Ananda Developments invests in the developing market for medical or therapeutic 
Cannabis derivatives, or related products, including but not limited to 
nutraceuticals, dietary supplements and cosmetic products which contain 
Cannabis or hemp derived cannabinoids. The Directors believe that this market 
is growing due to an increasing number of states in the USA, as well as other 
countries around the world, changing their laws to allow for products 
containing constituents of Medical Cannabis to be developed, approved and sold. 
A copy of the Company's Admission Document is available at 
Ananda's investment strategy is to invest in companies, projects or products 
that are either progressing medical or therapeutic Cannabis research and 
development, or are developing or have already developed, products that contain 
Cannabis derived cannabinoids and require funding to progress work plans or 
commercialise products. 

(END) Dow Jones Newswires

April 15, 2019 07:24 ET (11:24 GMT)